Sarcopenia Predicts Mortality and Hepatic Encephalopathy After TIPS in Older Adults With Cirrhosis and Improves Prognostic Scores
Authors:
Open Access
- 7 June 2026
- journal article
- research article
- Published by Wiley in Liver International
- Vol. 46 (7) , e70733
Abstract
Background and Aims: The role of transjugular intrahepatic portosystemic shunt (TIPS) in older adults remains controversial because of limited risk‐stratification tools. We aimed to assess whether sarcopenia and myosteatosis are independently associated with post‐TIPS mortality and overt hepatic encephalopathy (OHE) in patients aged ≥ 70 years, and whether adding sarcopenia to established prognostic scores improves discrimination for post‐TIPS mortality. Methods: This multicenter retrospective study included 115 consecutive patients with cirrhosis aged ≥ 70 years undergoing TIPS for refractory ascites or secondary prophylaxis of variceal bleeding. Sarcopenia and myosteatosis were assessed by computed tomography at L3. Post‐TIPS mortality and time to first OHE episode were analysed using Kaplan–Meier and Cox regression. Sarcopenia was integrated into established prognostic scores, and predictive performance was evaluated using time‐dependent ROC analyses. Results: Sarcopenia and myosteatosis were present in 60% and 80% of patients, respectively. During follow‐up, 49% died and 45% developed OHE. Sarcopenia was independently associated with both mortality and OHE, whereas myosteatosis and adipose‐tissue indices were not. Incorporating sarcopenia improved the discriminative performance of all scores, with MELD 3.0–sarcopenia showing the highest accuracy (AUC 0.845). Predicted survival probabilities clearly separated patients across MELD 3.0 categories according to sarcopenia status. For OHE, sarcopenia increased the risk while underdilated TIPS was protective, defining four distinct risk profiles. Conclusions: Sarcopenia is highly prevalent and independently predicts both mortality and OHE after TIPS in older adults. Its integration into prognostic tools enhances risk stratification and supports individualised decision‐making in this vulnerable population.Keywords
This publication has 49 references indexed in Scilit:
- Prevalence of sarcopenia in patients with chronic kidney disease: a global systematic review and meta‐analysisJournal of Cachexia, Sarcopenia and Muscle, 2024
- Diagnosis and Management of Cirrhosis and Its ComplicationsJAMA, 2023
- Mortality after transjugular intrahepatic portosystemic shunt in older adult patients with cirrhosis: A validated prediction modelHepatology, 2022
- Malnutrition, Frailty, and Sarcopenia in Patients With Cirrhosis: 2021 Practice Guidance by the American Association for the Study of Liver DiseasesHepatology, 2021
- Myosteatosis and prognosis in cancer: Systematic review and meta-analysisCritical Reviews in Oncology/Hematology, 2020
- Under-dilated TIPS Associate With Efficacy and Reduced Encephalopathy in a Prospective, Non-randomized Study of Patients With CirrhosisClinical Gastroenterology and Hepatology, 2018
- Fat‐free muscle mass in magnetic resonance imaging predicts acute‐on‐chronic liver failure and survival in decompensated cirrhosisHepatology, 2018
- Muscle Wasting and Sarcopenia in Heart Failure and Beyond: Update 2017ESC Heart Failure, 2017
- Sarcopenia Is Risk Factor for Development of Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt PlacementClinical Gastroenterology and Hepatology, 2017
- A multicenter study to define sarcopenia in patients with end‐stage liver diseaseLiver Transplantation, 2017